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Abstract 
Background: Advanced Therapy Medicinal Products are  gene therapy, somatic cell therapy or tissue 
engineered products regulated under (EC) 1394/2007 to ensure their free movement within the 
European Union while guaranteeing the highest level of health protection for patients.  Academic 
GMP manufacturing  centres are major contributors in the development of ATMPs and this study 
assessed the impact of regulations on them. 
Design and Methods: 747 European academic and non-industrial facilities were contacted and a 
representative sample of 50 replied to a detailed questionnaire.  Experienced centres were further 
selected in every Member State for semi-structured interviews.  Indicators of ATMP production and 
development success were statistically assessed and opinions about directive implementation were 
documented. 
Results: Facilities experienced in manufacturing cell therapy transplant products are the most 
successful in developing ATMPs. New centres lacking this background struggle to enter the field and 
there remains a shortage of facilities in academia participating in translational research. This is 
compounded by heterogeneous  implementation of the regulations across MS. 
Discussion: GMP facilities successfully developing ATMPs are present in all MS. However, the 
implementation of  regulations is heterogeneous between MS, with substantial differences in the 
definition of ATMPs and in the approved manufacturing environment. The cost of GMP compliance 
is underestimated by research funding bodies. This is detrimental to development of new ATMPs 
and commercialisation of any which are successful in early clinical trials.  
Academic GMP practitioners should strengthen their political visibility and contribute to the 
development of functional and effective EU legislation in this field. 
Key words 
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Introduction 
Advanced Therapy Medicinal Products (ATMPs) are medicinal products for human use, based on 
gene therapy, somatic cell therapy or tissue engineering. A rapidly growing area in translational 
research, they represent the ‘next generation’ of complex medicines for complex diseases and pose 
particular challenges to medicines regulation. 
 
Regulation (EC) No 1394/2007 defined ATMPs and was designed to ensure their free movement 
within the European Union (EU), to facilitate their access to the EU market and to foster the 
competitiveness of European pharmaceutical companies while guaranteeing the highest level of 
health protection for patients1. ATMPs are regulated as pharmaceutical products and the Regulation 
led to the amendment of the EU Medicinal Products Directive 2001/83/EC with Directive 
2009/120/EC. Cellular starting materials are required to be procured under the national licensing 
structure enforcing the EU Directives 2004/23/EC, 2006/17/EC and 2007/83/EC; the Tissues & Cells 
Directives. All manufacturing of products requires compliance with the standards of Good 
Manufacturing Practice (GMP) to ensure their quality, safety and efficacy. 
 
Academic GMP facilities are major contributors to the development of ATMPs2. They respond to 
clinical needs and provide medicinal products in an environment which, albeit compliant with 
industrial standards, is by definition not industrial. They find themselves in a challenging position 
between various, sometimes conflicting, interests in the transition of ATMPs from bench to bedside. 
European investigator-initiated multicenter trials on ATMPs critically depend on academic GMP 
facilities. 
 
The EC-funded project “The impact of Regulation (EC) No 1394/2007 on the development of 
Advanced Therapy Medicinal Products (ATMPs): an academic perspective” (Grant No: 260773) was 
designed to assess the impact of Regulation (EC) No 1394/2007 and the Directives on which it was 
based on academic manufacture and clinical trial of ATMPs. We describe here one of the outcomes 
from the project - the results of the European survey and subsequent one-to-one interviews 
conducted among non-industry facilities involved in ATMPs. We determined whether specific facility 
characteristics are linked with success in ATMP production and development and if success is 
predominant in certain countries. We also investigated whether facilities believed that the 
regulation of these products as medicines has hindered innovation in the field. 
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Methods 
 
Study Design 
 
A short questionnaire and a longer, more detailed, questionnaire were constructed.  The short 
questionnaire asked if the facilities (i) currently produce ATMPs and/or intend to produce ATMPs in 
the future, (ii) would be interested in establishing a network, over the next 2 years, of non-industrial 
GMP institutions in Europe – giving academic GMP a voice and (iii) would be willing to complete a 
longer, more detailed questionnaire in the near future.  
 
To structure the longer questionnaire, in-depth discussions on prospective topics were conducted 
by the project consortium General Assembly with input from statisticians, most notably at the 
workshop “Manufacture of Advanced Therapies: Academia meets Industry” 3.  
 
The long (and short) questionnaire(s) were in English and it was ensured that all questions were easy 
to understand with no jargon and easily translated. To avoid missing or illegible responses, tick boxes 
were used. The questionnaires were addressed to only one senior person per centre. The first 
section of the short questionnaire gave a brief overview of the survey and described its aims and 
objectives with a contact address and email. The short questionnaire stated that there would be 
anonymity between centres i.e. centres would be unidentifiable when the results were reported. 
The study was in compliance with the Data Protection Directive (1995/46/EC) and with the Privacy 
and Electronic Communications Directive (2002/58/EC). 
 
Newcastle University was responsible for the generation of the short email questionnaire. The long 
questionnaire was designed by Newcastle University who worked closely with Lunds Universitet 
(Sweden) in order that it could be made available electronically on the Academic GMP website. The 
long questionnaire included questions which asked about ATMP production/development, 
collaboration, facility size, consultation with regulatory bodies and opinion as regards Regulation 
(EC) No. 1394/2007.  
 
Contacts for receipt of the short questionnaire were based upon their affiliation with the Joint 
Accreditation Committee of the International Society for Cellular Therapy and European Group for 
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Blood and Marrow Transplantation (JACIE), European Group for Blood and Marrow Transplantation 
(EBMT), International Society for Cellular Therapy (ISCT), Foundation for the Advancement in Cancer 
Therapy (FACT), European Clinical Research Infrastructures Network (ECRIN) and Committee for 
Advanced Therapies (CAT).   Those approached also included coordinating scientists of all identified 
Framework Programme (FP) - funded projects related to cell therapy, stem cells, regenerative 
medicine and/or gene therapy, members of the UK Stem Cell Users Group and personal 
acquaintances.  
 
Statistical Analysis 
 
Relationships between questionnaire responses and ATMP development and production success 
were assessed. The methods used included statistical inference, multiple correspondence analysis, 
ordinal logistic regression modelling and chi-squared based statistics. SAS (version 9.2), Minitab 
(version 16) and SPSS (version 19) were used for statistical analysis. The data from the telephone 
interviews were not subjected to statistical analysis but were used empirically to clarify responses to 
the questionnaires for improved interpretation of the data. 
 
Response Rate 
 
In total, 747 contacts in 31 European countries (25 EU Member States [MS], 4 candidate EU MS and 
2 further members of the European Free Trade Association (EFTA)) were approached and were sent 
the short questionnaire. Of these contacts, 94 facilities (17 EU MS and 1 candidate EU MS) returned 
a completed questionnaire of whom 85 said they would be interested in completing the longer, 
detailed questionnaire. It may be argued that more advanced facilities were likely to reply, but we 
did see a lot of interest among those who were less advanced – these facilities wanted to improve 
and wished to highlight difficulties they were having with current legislation.   
 
After distributing the long questionnaire to the interested parties, 50 completed questionnaires 
were received from 11 countries (of which 10 were EU MS and 1 was a candidate EU MS). The 
number of facilities in each of the contributing countries is shown in Figure 1. 
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For the majority of countries, a similar percentage of facilities from each country is observed in our 
sample as that which occurs in the actual population of 747 European contact points (Table 1), 
rendering this a representative sample chosen by proportional allocation.4 
The remaining non-responding countries had very few facilities in the population of 747 contacts (all 
making up less than 2% of the total).  To address the issue of non-response, telephone interviews 
were conducted with selected facilities. 
 
Links with Success 
The maximum number of types of ATMPs developed in a year by the facility and the maximum 
number of types of ATMPs produced in a year by the facility were chosen as initial indicators of 
‘ATMP success’. The respondee was given the opportunity to enter the number of ATMP types 
produced (developed) in each of several listed years.  The  maximum number of types of ATMPs 
produced (developed) in a year was chosen as an accurate indicator of success as (i) averaging 
across years may produce inaccurate results as respondees may have erroneously recorded the 
same ATMP as being produced/developed across several years (ii) summing across years may be 
inaccurate as a facility in operation over many years, producing/developing ATMPs sporadically, 
may have a greater grand total than a newer facility producing/developing many ATMPs in a single 
year.  The variable measuring success therefore took an ordinal (categorical) form.  Initially, in order 
to establish univariate associations between each question response and ‘success’, ordinal logistic 
regression was employed alongside chi-squared based statistics.   
 
Results 
 
The questions most significantly associated with ATMP development and production on a univariate 
level (p<0.1) are shown in Tables 2a and 2b respectively. It is of note that there was evidence that 
questions 10, 37, 50 and 58 are related to both development and production success. 
The questionnaire responses provided clear evidence that: 
- Those centres which were involved in the initial development of new ATMPs were also those 
which successfully achieved GMP-comliant production for clinical trials. In such a novel and 
developing field this is to be expected and probably explains why such a high proportion of ATMP 
trials remain in the academic domain and have not yet progressed to industrial development. The 
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development phase of these cellular drugs is highly experimental and still is largely investigator-led 
in the EU and US. Many ATMPs in early trial are not being developed with the ultimate aim of 
commercial success. This relationship between development success and translation to GMP 
production was confirmed by the observation of the converse significant link, i.e. that those who 
produce know how to develop. 
- It was also apparent that the centres which successfully translated to clinical trial were those 
which interacted with appropriate regulatory authorities for advice rather than just as part of a 
statutory regualtory process. This may be interpreted in one of two ways. Either the advice is 
essential for successful conversion to GMP and trial, or, only those centres which are already 
competent in GMP manufacture and trials design are confident enough to interact with their 
regulatory authority. Understanding these interactions was a key part the telephone interviews.  
 
- Academic facilities experienced in ATMP development regularly pass inspections – these facilities 
understand how to be compliant with GMP standards and are comparable with (and potentially 
competitive with) industry. 
- These experienced facilities mostly have a pre-existing background in manufacturing non-
medicinal, minimally manipulated cell therapies (e.g. haematopoietic stem cell transplant products 
and associated lymphocyte infusion). They have existing quality systems for compliance with 
national regulation of tissues and cells and are better staffed than purely academic laboratories 
trying to develop ATMPs in isolation. 
- It is difficult for new centres to enter the field under existing regulations because of the investment 
required in GMP manufacturing resources (staff and buildings). In many EU MS there remains a lack 
of GMP-compliant facilities in Academia that can take part in the field of translational research. 
- There is a general paucity of and need for quality control programmes for qualification and 
standardisation of these products as they progress through development in an attempt to attain 
marketing authorisation in the EU and beyond. 
 
The technique of multiple correspondence analysis5,6,7,8 (MCA) utilised the categorical variables 
most significantly associated with ‘success’ (p≤0.05). MCA generates a map – nearby points are 
similar as regards how they responded.  The map can be shown multi-dimensionally. The first few 
dimensions are the most important - they give the best picture of the data (i.e. they account for the 
most variability in the data).  We generate two maps – one showing which facilities are similar and  
the other showing which questions responses occur together (e.g. it may be the case that when a 
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facility replies “yes” to question A, they reply “yes”to question B – hence “QA_yes“ and “QB_yes“ 
would occur together on the plot). In this study, for both development and production, only the first 
two dimensions were relevant, hence 2-dimensional plots were generated. Figures 2a and 3a show 
the similarity of the facilities – the maximum number of ATMP types developed/produced  per year 
for each facility is superimposed.  Figures 2b and 3b show the similarity as regards question 
response. The proportion of total variance accounted for by each dimension is given in Figures 2a 
and 3a.  Technically, for MCA, the map has potentially min{I-1,J-Q} dimensions, where I is the 
number of facilities, Q is the number of questions used for the analysis and J is the total number of 
question response categories.  The only relevant dimensions in MCA are those for which the 
eigenvalue (principal inertia) of the indicator matrix is greater than 1/Q7,8.  The total (principal) 
inertia is also called the total variance. The questions described below in the interpretation of the 
MCA contribute strongly to each dimension (aggregated contribution value > 1/Q 7,8). 
 
Figure 2a and Figure 2b show that, for development, facilities developing the most types of ATMPs 
are also producing ATMPs to GMP standard (Q4) and know that they can get formal advice 
regarding ATMPs via the Scientific Advice Working Party (SAWP) (Q37). They are also those sites 
which have consulted, and are satisfied with, their national regulatory body (e.g. Paul-Ehrlich-
Institute (PEI), Medicines and Healthcare products Regulatory Agency (MHRA)(Q50). Also, these 
facilities are regularly externally inspected against established quality standards (GMP/ European 
Union Tissues and Cells Directive (EUTCD)) (Q54).  
 
Figure 3a and Figure 3b show that, for production, facilities producing the most types of ATMPs 
have no issues validating processes relating to ATMP manufacture (Q41) which, given the shortage 
of clinical material for development, is interesting. The centres producing the most types of ATMPs 
also communicate with their national regulatory body (Q50), and they have been producing ATMPs 
before the introduction of Regulation (EC) No. 1394/2007 (Q58). Substantially modified cell 
therapies have been defined as medicines since enactment of 2001/83/EC in each MS so many of 
these groups active before Regulation 1394/2007/EC was published were already manufacturing in 
full compliance with GMP under national authorisations. 
 
An additional question asked if the facility had any external collaborations for development, 
production and/or quality control of cell therapies. It was apparent that collaborations were more 
common in facilities who are developing ATMPs as well as non-medicinal cell therapies (p=0.015, 
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result not tabulated); presumably indicating that some academic ATMP developers collaborate with 
external manufacturers, both academic and industrial. University/Medical School facilities which 
manufacture ATMP products tend to work in isolation and further collaboration/co-operation with 
other centres would appear to be of benefit. 
Telephone Interviews 
Following preliminary analysis of the questionnaires, specific questions or areas of anomaly were 
chosen to be explored in greater depth by telephone interviews with one or more experts in ATMP 
development in each MS. Twenty two interviews were conducted with centres in sixteen EU MS. The 
interviews were performed in English or the native language of the interviewee in a semi-structured 
fashion to address procedures implemented in their facility, regulatory problems encountered and 
general understanding of implementation of the relevant regulations in their MS.  Interviewees were 
approached in all MS of the EU, irrespective of whether they had responded to any of the 
questionnaires. This can be considered (disproportional) stratified sampling. 
The interviews provided the most detailed information regarding the heterogeneous 
implementation of the Directives and the Regulation across the EU and the impact this 
heterogeneity has on development: 
- The definition of a cell-based medicinal product, a gene transfer medicinal product or a 
tissue engineered product as an ATMP, despite Regulation 1394/2007/EC, is not 
harmonised.  Even if one requests a classification from the European Medicines Agency 
(EMA) it is not legally binding, and each member state may, and often does, classify the 
same product differently. One such example was a case of three similar products consisting 
of human natural killer (NK) cells expanded and activated in ex-vivo culture over several 
weeks as an anti-cancer immunotherapy. In Spain, Germany and in Switzerland these 
expanded products were classified as an ATMP whilst in France they were deemed “not 
substantially modified” and thus not regulated as a medicine. A far less manipulated NK cell 
product in which the cells were simply activated and not expanded was classified as an 
ATMP in the UK.  
- All products have been taken to clinical trial successfully but the routes available for future 
development of these products remains very unclear. One might presume that the products 
regulated as medicines could follow a simple drug development pathway through 
increasingly complex trial and ultimately generate sufficient data for a marketing 
authorisation application to EMA. However, how would that be handled in France where an 
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identical product is able to be manufactured as a non-medicinal transplant product? 
Presumably the licensed NK product would have no legal protection from competition from 
an unlicensed alternative. This is already happening in some EU MS where academic and 
hospital facilities are allowed to make an autologous chondrocyte preparation in direct 
competition with the licensed product from Tigenix. Moreover, in the case of the NK cell 
product which is under clinical trial as a “non-substantially modified” preparation it is very 
unclear how this might be developed if the clinical trial were successful. Since it was not 
regulated as a medicine it cannot progress down a drug development route and is not 
commercially valuable. Without formal efficacy trials which are suitably controlled and 
powered it is hard to see how these non-medicinal products can be provided to the wider 
community beyond those in the initial small academic study.  All correspondents confirmed 
that transition to GMP manufacture added significant costs but agreed that it was an 
essential process and that these complex therapies needed regulation. Interestingly, of 
those asked, none supported the concept of a lower standard of GMP for ATMPs than for 
conventional medicines nor was there a feeling that academic groups should be allowed to 
work to a lower GMP standard than industry but all interviewees shared the belief that a 
risk-based approach to compliance with pharmaceutical standards is required in the 
development of ATMPs.  
- The majority of ATMPs in development are patient-directed or only able to be produced in 
very small batch sizes and it is unlikely that many will fit the conventional pharmaceutical 
model of a single batch providing treatments for thousands of patients.  
- Many respondents reported favourable interactions with local regulatory authorities which 
operated a pragmatic approach to risk-based assessment of manufacturing procedures. 
Others reported extreme difficulties with obtaining approval for manufacture of specific 
products due to unrealistic expectations of product qualification by their individual 
competent authority. As an example, bone marrow derived mesenchymal stromal cells are 
commonly produced for therapeutic use across the EU. In some member states they are not 
even classified as medicines. In those where they are deemed to be ATMPs, most competent 
authorities accept release criteria based on sterility, four parameter immunophenotype as 
definition and >80% viability. However, a competent authority (CA) in a single MS has 
required chromosomal stability assays on all mesenchymal stromal cell (MSC) cultures which 
renders the trial unsustainable. Since clinical trial approvals remain within the domain of 
individual MS this will continue to be a problem for ATMP development and, since many are 
directed at orphan indications, is already hindering research which needs to be conducted 
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across multiple MS to reach acceptable rates of recruitment.  All participants in the 
telephone survey said that the burden of paperwork associated with GMP, and Good Clinical 
Practice (GCP), compliance was a hurdle for small academic manufacturers and that open 
access availability of common procedures and reagent/process validations would be 
enormously valuable. Universities and research funding bodies do not understand the 
administrative challenges of GMP/GCP compliance and do not resource them. These outputs 
are not publishable and therefore do not contribute to academic returns against which the 
university is assessed by its peers.  It was not felt that the regulatory burden in the EU had 
yet put academic clinical investigators at a disadvantage to competitors overseas although 
one respondent reported that patients are travelling to another EU MS to gain access to an 
experimental ATMP which they are unable to obtain regulatory approval to manufacture in 
their centre. There is widespread concern that the non-integrated approach to regulation 
will lead to patients travelling to other jurisdictions for novel therapies; both within and 
beyond the EU.  
A comprehensive literature search of published papers and conference abstracts showed that the EU 
lags behind the US with regard to cell therapies in clinical trials; both academic and industry-led. In 
contrast to the EU, US GMP facilities for manufacturing for phase I/II and phase II trials are not 
subject to regulatory inspection and the burden of compliance is lower. The most active countries in 
this field outside of EU/USA are South Korea and Brazil where the burden of GMP compliance is also 
lighter.  
Three aspects of the current regulation of ATMPs were repeatedly of concern to respondents. First, 
the provision of pre-clinical data for compilation of the medicinal product dossier to investigational 
ATMPs (IMP ATMPs) often leads to use of very contrived animal models. There is a significant risk of 
underestimating toxicity of human-specific biologic reagents when evaluated in animal models, even 
primates, as pharmacologic activity and unanticipated adverse side effects may be species-specific 
(9). Standard animal models may also not be predictive of toxicity due to differences in lifespan, and 
because the equivalent human application cannot be adequately mimicked. The testing of an 
“equivalent” ATMP derived from tissues from the experimental host is flawed also as the starting 
materials (cytokines, culture media, supplements and even culture vessels) are likely to be 
substantially different to the human product. This led us to conclude that the development of 
ATMPs requires a paradigm shift in the approach to pre-clinical testing required for clinical trial 
authorisation (CTA) (2, 10, 11). 
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The second issue requiring solution is the statutory need for a Qualified Person (QP) for the formal 
release of investigational medicinal products (IMPs) in the EU. In most MS the local CA approves 
routine pharmaceutical QPs for release of complex ATMPs. Notwithstanding the question of their 
competence with products considerably beyond their general field of expertise, many QPs are 
unwilling to accept the risks of releasing ATMPs and thus academic trialists face difficulties with 
regard to the release of investigational ATMPs. Training for pharmacy QPs in the manufacture of 
ATMPs is essential but currently lacking. In the US, there is no requirement for QP release of 
investigational medicines. This shortage of competent QPs also leads to a very significant added 
expense in ATMP manufacture which is compounded by the fact that these products usually have a 
very small production run with small or even single product batches. Many ATMPs are patient-
specific or have a final dosing which is required immediately prior to administration. The need for QP 
release of each batch when a single batch treats a single patient is prohibitively expensive and may 
even be logistically impossible in some cases.  
The third consistent and most contentious issue arising from the telephone interviews and the 
questionnaires was the lack of harmonisation of implementation of the Hospital Exemption Clause 
(HEC) in Regulation 1394/2007/EC across the MS. Several MS have not yet implemented a structure 
to assign HEC production licences as of the end of 2012, and in those who have done so there are 
wide differences in how it may be used. Most MS have applied annual limits to the numbers of a 
specific product type which can be manufactured under a hospital exemption clause (HEC) licence, 
presumably in response to the stated requirement for “non routine” production in the Regulation, 
whilst others apply no limits. The limit on numbers of individual ATMPs under the HEC is seen as 
counterproductive by over 80% of respondents. It is another potential cause of patient migration 
from their own MS to an adjacent MS or non-EU country to receive a treatment simply because an 
arbitrary maximum number of patients have been treated in a single centre in one year. Clarification 
of the definition of “non routine” from the Commission to the CAs in each MS is needed. 
The use of the HEC for clinical trial product manufacture is forbidden in all MS as required in the 
Regulation. However, several CA are encouraging the use of HEC to produce ATMPs for first-in-man 
cases, allowing the data arising from these to be used as part of the investigational medicinal 
product dossier for subsequent clinical trial applications. This is in line with a recommendation by 
EMA CAT regarding the use of clinical data from first-in-man studies to replace pre-clinical animal 
studies where appropriate (11). Indeed some CA are referring to these first-in-man compassionate 
use cases as a new “phase 0” type of clinical study. The continued availability of the HEC for this type 
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of application and for the provision of ATMPs which will never be suitable for a marketing 
authorisation was regarded as essential by all respondents. 
 
 
Discussion and Conclusion 
 
This is the first ever survey of a representative sample of European academic GMP facilities involved 
in the development and production of ATMPs.  Indicators of ATMP success were assessed and 
opinion was gathered regarding implementation of current EU legislation.  Results indicated that 
associations do exist between facility characteristics/behaviour and ATMP success:  development, 
production and communication with the authorities are unquestionably key factors for success.  
Experience is also inextricably linked with success  – with experienced facilities in ATMP 
development often being those which are better staffed  - these facilities “know GMP” i.e. they are 
comparable with (and competitive with) industry.  However, it is difficult for new centres to enter 
the field under existing regulations and there is still a lack of facilities in academia that can take part 
in the field of translational research. Universities lacking these resources will fall behind in delivery 
and commercialisation in this field of medicine.  Producing GMP-compliant ATMPs for clinical use in 
trials or as compassionate treatment is expensive in capital and manpower resources and it is the 
ongoing manpower needs which are frequently overlooked by academic centres with no history of 
cell therapy manufacture. The successful academic centres are predominantly those with a previous 
history of non-medicinal cell therapy (transplant products) provision which had pre-existing quality 
management systems and the staff to maintain them.  
The need for QP release of investigational ATMPs presents difficulties in some MS, specifically 
because the batch size is often a single, patient-specific product. The lack of requirement for QP 
release by the FDA makes academic and industrial development of patient-specific ATMPs 
substantially easier in the US. 
Collaboration is also important, and those facilities who manufacture ATMP products in a 
University/Medical School would benefit from co-operation with other centres.  The need for (and 
lack of) quality control programmes is also important.   
 The inconsistencies in the implementation of the Regulation are a considerable barrier to 
development of ATMPs across the EU but this is largely due to the myriad differences in national 
drug laws which underpin the ATMP Regulation.  
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Figure 1 Pie Chart showing distribution of respondents in 11 European countries (N=50) 
A – Germany, B – UK, C – Spain, D – Netheralnds, E – Italy, F – Belgium, G – Austria, H – France, I – 
Turkey, J – Eire, K - Romania 
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Figure 2a  Two dimensional multiple correspondence plot for ATMP development – nearby facilities 
reply similarly to the questions.  Country identification letter is displayed alongside maximum 
number of ATMP types developed per year. Proportion of total variance for dimension 1=38% 
(eigenvalue=0.47); for dimension 2=24% (eigenvalue=0.30).  Red circles indicate least successful 
facilities, green circles indicate most successful facilities. 
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Figure 2b  Two dimensional multiple correspondence plot for ATMP development showing similarity 
between question responses.  Red circles indicate question responses linked to least successful 
facilities, green circles indicate those linked to most successful facilities. 
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Figure 3a  Two dimensional multiple correspondence plot for ATMP production – nearby facilities 
reply similarly to the questions.  Country identification letter is displayed alongside maximum 
number of ATMP types produced per year. NA= maximum number of types of ATMP produced not 
available.  Proportion of total variance for dimension 1=35% (eigenvalue=0.35); for dimension 
2=32% (eigenvalue=0.32).  Red circles indicate least successful facilities, green circles indicate most 
successful facilities. 
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Figure 3b  Two dimensional multiple correspondence plot for ATMP production showing similarity 
between question responses.  Red circles indicate question responses linked to least successful 
facilities, green circles indicate those linked to most successful facilities. 
 
 
210-1-2
2
1
0
-1
-2
Dimension 2
D
im
e
n
s
io
n
 1
Q41_yes
Q41_no
Q58_yes
Q58_no
Q50_yes Q50_no
Q10_yes
Q10_no
 
 
22 
 
 
 
Table 1  Comparison of proportion of respondents in each country  
Country Percentage of facilities 
in sample N=50 
Percentage of facilities 
in population N=747 
p value1 
A 30% 19% 0.067 
B 20% 16% 0.427 
C 14% 4% 0.045 
D 8% 9% 1.000 
E 8% 10% 1.000 
F 6% 5% 0.748 
G 4% 4% 0.714 
H 4% 7% 0.571 
I 2% 1% 0.325 
J 2% 2% 0.546 
K 2% 1% 0.325 
1 Exact p-value - 2 sample proportions test 
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Table 2a Questions associated with ATMP development success 
 p-value1 
Question  
Q54 The facility regularly passes GMP/ European Union Tissues and Cells 
Directive (EUTCD) inspections for ATMPs produced/intended to be 
produced  
 
0.015 
Q37 The facility knows it can get formal advice regarding ATMPs via the 
Scientific Advice Working Party (SAWP)  
 
0.02 
Q4 The facility is producing ATMPs (Q4), 0.031 
Q50 The facility has consulted  with  - and is satisfied with - a national 
regulatory body (e.g. Paul-Ehrlich-Institute (PEI), Medicines and 
Healthcare products Regulatory Agency (MHRA) 
0.036 
Q10 The facility is performing purifications other than immunomagnetic 
purifications  
0.055 
Q20 Increased number of technical/academic personnel involved directly 
in ATMP development 
 
0.073 
Q7 The facility is producing stem cell products as ATMPs (e.g. 
Mesenchymal stem cells)   
 
0.074 
Q58 The facility produced ATMPs before the introduction of Regulation 
(EC) No. 1394/2007. 
 
0.082 
Q11 The facility is performing cell manipulations (for example, 
expansion)  
0.1 
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1Exact p-value – chi squared test  
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Table 2b Questions associated with ATMP production success 
 p-value1 
Question  
Q58 The facility produced ATMPs before the introduction of Regulation 
(EC) No. 1394/2007 
0.022 
Q10 The facility is performing purifications other than immunomagnetic 
purifications  
0.022 
Q41 The facility has no issues validating processes relating to ATMP 
manufacture   
 
0.033 
Q50 The facility has consulted  with  a national regulatory body (e.g. 
Paul-Ehrlich-Institute (PEI), Medicines and Healthcare products 
Regulatory Agency (MHRA) 
0.05 
Q19 The facility is developing ATMP products in a University/Medical 
School 
 
0.075 
Q31 The facility took part in quality control programmes for assays (e.g. 
National External Quality Assessment Service (NEQAS)).   
 
0.078 
Q37 The facility knows it can get formal advice regarding ATMPs via the 
Scientific Advice Working Party (SAWP)  
 
0.1 
1Exact p-value – chi squared test  
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